3Ikonomidis I, Parissis JT, Paraskevaidis I, et al. Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure [J]. Eur J Heart Fail, 2007, 9 (12): 1172-1177. 被引量：1
4Parissis JT, Andreadou I, Bistola V, et al. Novel biologic mechanisms of levosimendan and its effect on the failing heart [J].Expert OpinInvestig Drugs, 2008, 17 (8): 1143-1150. 被引量：1
5Parissis JT, Adamopoulos S, Antoniades C, et al. Effects of levosimendan on circulating pro inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure [J].Am J Cardiol, 2004, 93 (10):1309-1312. 被引量：1
6Farmakis D, Parissis JT, Bistola V, et al. Plasma B-type natri uretic peptide reduction predicts long-term response to levosimendan therapy in acutely deeompensated chronic heart failure [J] Int J Cardiol, 2010, 139 (1): 75-79. 被引量：1
7Tziakas DN, Chalikias GK, Hatzinikolaou HI, et al. Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure [J]. Cardiovasc Drugs Ther, 2005, 19 (6): 399-402. 被引量：1
8Parissis JT, Andreadou I, Markantonis SL, et al. Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure [J]. Atherosclerosis, 2007, 195 (2): e210-e215. 被引量：1
9Parissis JT, Karavidas A, Bistola V, et al. Effects of levosimendan on flow mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure [J]. Atherosclerosis, 2008, 197 (1): 278-282. 被引量：1
10Lehtonen L, Poder P. The utility of levosimendan in the treatment of heart failure[J].Ann Med, 2007, 39 (1): 2-17. 被引量：1
8Lemos J, McGuire D, Drazner M, et al. B-type natriuretic piptide in cardiovascular disease J. Lancet,2003,362 (14) :316-322. 被引量：1
9Lee SC, Stevens TL, Sandberg SM, et al. The potential of brainna- triuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail, 2002,8(3) :149-154. 被引量：1
10Dec GW. Acute decompensated heart failure:the shrinking role of inotropic therapy. Am Coll Cordial,2005,46( 1 ) :65-67. 被引量：1
